Gradient Investments’s Enanta Pharmaceuticals ENTA Stock Holding History

Gradient Investments’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-268	Closed	-$17K	–	1127
2019 Q4	$17K	Hold	268	–	–	﹤0.01%	589
2019 Q3	$16K	Hold	268	–	–	﹤0.01%	556
2019 Q2	$23K	Hold	268	–	–	﹤0.01%	494
2019 Q1	$26K	Hold	268	–	–	﹤0.01%	412
2018 Q4	$19K	Hold	268	–	–	﹤0.01%	457
2018 Q3	$23K	Hold	268	–	–	﹤0.01%	468
2018 Q2	$31K	Hold	268	–	–	﹤0.01%	409
2018 Q1	$22K	Hold	268	–	–	﹤0.01%	457
2017 Q4	$16K	Buy	+268	New	+$13.4K	﹤0.01%	507
2017 Q3	–	Sell	-268	Closed	-$10K	–	367
2017 Q2	$10K	Hold	268	–	–	﹤0.01%	479
2017 Q1	$8K	Buy	+268	New	+$8.35K	﹤0.01%	541

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Gradient Investments's ENTA Position: Q1 2020 in Review

Gradient Investments sold out of Enanta Pharmaceuticals (ENTA) in Q1 2020, closing a stake of 268 shares — an estimated $17K sold.

Gradient Investments first reported a position in ENTA in Q1 2017 and held it in 11 quarters. The position peaked at $31K in Q2 2018. 156 funds tracked by Wall St. Rank hold ENTA as of Q1 2020.

Gradient Investments reported no remaining Enanta Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
Gradient Investments sold 268 Enanta Pharmaceuticals shares in Q1 2020, an estimated $17K.
Gradient Investments first reported a position in Enanta Pharmaceuticals in Q1 2017 and held it in 11 quarters.
Gradient Investments's Enanta Pharmaceuticals position peaked at $31K in Q2 2018.
156 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2020.

Based on Gradient Investments's 13F filing for Q1 2020, filed 7 Apr 2020.